Mayne Pharma launches generic Ritalin LA in new strength
Mayne Pharma is introducing its generic Ritalin LA (methylphenidate extended-release) capsules in 10-mg dosage strength — the first available in this strength. The product is indicated to treat attention deficit hyperactivity disorder.
“This launch reinforces Mayne Pharma’s commitment to expanding its on-market portfolio,” Mayne Pharma CEO Scott Richards said. “This will be the first generic alternative of the 10-mg dose strength, providing more choices to patients in terms of medication affordability. Mayne Pharma directly markets more than 55 products, and has a growing pipeline of more than 35 generic drug products targeting U.S. markets with [IQVIA] sales greater than $5 billion.”
The generic Ritalin LA 10-mg capsules will join the companies preexisting line of 20-, 30-, 40- and 60-mg dosage strengths of the product. Brand sales of Ritalin LA were roughly $21 million for the 12 months ended December 31, 2017, according to IQVIA data.
“This launch reinforces Mayne Pharma’s commitment to expanding its on-market portfolio,” Mayne Pharma CEO Scott Richards said. “This will be the first generic alternative of the 10-mg dose strength, providing more choices to patients in terms of medication affordability. Mayne Pharma directly markets more than 55 products, and has a growing pipeline of more than 35 generic drug products targeting U.S. markets with [IQVIA] sales greater than $5 billion.”
The generic Ritalin LA 10-mg capsules will join the companies preexisting line of 20-, 30-, 40- and 60-mg dosage strengths of the product. Brand sales of Ritalin LA were roughly $21 million for the 12 months ended December 31, 2017, according to IQVIA data.